Abivax SA
ABVX117.670USD
+6.960+6.29%
收盘 02/06, 16:00（美东）报价延迟15分钟
0.00总市值
--市盈率 TTM
关于 Abivax SA 公司
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA简介
公司代码ABVX
公司名称Abivax SA
上市日期Jun 26, 2015
CEOde Garidel (Marc)
员工数量- -
证券类型Depository Receipt
年结日- -
公司地址7-11 Boulevard Haussmann
城市PARIS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编75009
电话33153830963
网址https://www.abivax.com/
公司代码ABVX
上市日期Jun 26, 2015
CEOde Garidel (Marc)
Abivax SA公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 1月19日 周一
更新时间: 1月19日 周一
持股股东
股东类型
持股股东
持股股东
占比
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.01%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
其他
73.39%
持股股东
持股股东
占比
TCG Crossover Management, LLC
9.67%
UBS Financial Services, Inc.
6.01%
Darwin Global Management Ltd
4.30%
Point72 Asset Management, L.P.
3.98%
Cormorant Asset Management, LP
2.65%
其他
73.39%
股东类型
持股股东
占比
Hedge Fund
33.85%
Investment Advisor
23.60%
Investment Advisor/Hedge Fund
8.93%
Research Firm
2.98%
Venture Capital
2.18%
Private Equity
1.77%
Pension Fund
1.00%
Bank and Trust
0.02%
其他
25.67%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
216
53.64M
52.23%
+104.02K
2025Q3
210
53.54M
52.22%
+19.70M
2025Q2
81
30.74M
57.27%
-1.09M
2025Q1
75
31.82M
50.24%
-38.10K
2024Q4
68
29.91M
44.59%
+2.48M
2024Q3
54
27.43M
45.93%
-700.83K
2024Q2
51
33.52M
46.25%
-227.21K
2024Q1
46
28.78M
34.33%
+7.18M
2023Q4
33
27.04M
1.75%
+20.54M
2023Q3
1
5.40M
0.00%
--
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
TCG Crossover Management, LLC
7.11M
9.67%
+1.05M
+17.42%
Sep 30, 2025
UBS Financial Services, Inc.
4.46M
6.06%
+4.29M
+2560.74%
Sep 30, 2025
Darwin Global Management Ltd
3.16M
4.3%
+3.16M
--
Sep 30, 2025
Point72 Asset Management, L.P.
2.93M
3.98%
+2.76M
+1642.45%
Sep 30, 2025
Cormorant Asset Management, LP
1.95M
2.65%
-180.00K
-8.45%
Sep 30, 2025
Paradigm BioCapital Advisors LP
1.56M
2.13%
+1.56M
--
Sep 30, 2025
Caligan Partners, LP
1.45M
1.97%
-222.48K
-13.29%
Sep 30, 2025
Fidelity Management & Research Company LLC
1.43M
1.94%
+417.90K
+41.26%
Sep 30, 2025
Fred Alger Management, LLC
1.23M
1.67%
+40.31K
+3.38%
Dec 31, 2025
Adar1 Capital Management LLC
1.35M
1.84%
-1.72M
-56.02%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Simplify Health Care ETF
2.86%
Harbor Health Care ETF
0.7%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
占比2.86%
Harbor Health Care ETF
占比0.7%
Fidelity Nasdaq Composite Index ETF
占比0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0%
Innovator IBD Breakout Opportunities ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
